Rapid Determination of Montelukast in Human Plasma by LC-ESI-MS/MS and Its Application to a Bioequivalence Study

Abstract

A rapid liquid chromatography–electrospray ionization–tandem mass spectrometry (LC-ESI-MS/MS) method was developed for the determination of montelukast in human plasma. The extraction of montelukast from plasma (300 µL) involved protein precipitation. Quantitation was performed using LC-ESI-MS/MS, operating in the positive ion and selective reaction monitoring (SRM) mode. The total chromatographic run time for the analysis was 1.5 min. A linear dynamic range was established from 5 to 800 ng mL^?1 for montelukast. The method was fully validated especially with regard to real subject sample analysis. It was successfully applied to a bioequivalence study in 18 healthy human subjects under fed condition (human subjects were allowed to eat as per the prescribed diet for bioequivalence study).     

Determination of Atovaquone in Human Plasma by LC-MS-MS and Its Application to a Bioequivalence Study

A sensitive and selective method for the determination of atovaquone in human plasma was developed and validated. The procedure employed the use of an internal standard (chlorothalidone) and a solvent extraction step. Detection was by electrospray ionization tandem mass spectrometry with multiple reaction monitoring. The method showed a linear range from 50 to 2,000 ng mL^?1. The extraction recovery was determined to be 84.91 ± 6.42% (SD), the intra- and inter-day assay accuracy (relative error) was within 7.57% and precision (RSD) was below 6.06%. The method was successfully employed to analyze plasma samples and evaluate the pharmacokinetics of atovaquone in human volunteers.     

Determination of Chlorzoxazone in Rat Plasma by LC-ESI-MS/MS and Its Application to a Pharmacokinetic Study

A sensitive LC-ESI-MS/MS method for determination of chlorzoxazone in rat plasma has been developed. Chromatographic separation was achieved on a Zorbax SB-C₁₈ column, with 45:55 (v/v) acetonitrile–water as the mobile phase. A LC-ESI-MS/MS was performed in a multiple reactions monitoring (MRM) mode using target ions m/z 167.5→131.6 for chlorzoxazone and m/z 230.7→185.6 for phenobarbital (internal standard). The calibration plots were linear over the range of 10.0–2,000 ng/mL. Intra-day and inter-day precisions were better than 5.1% and 6.8%, respectively. The validated method was successfully used to analyze the drug in samples of rat plasma for pharmacokinetic study.     

Determination of Tiopronin in Human Plasma and Pharmacokinetics by LC-ESI-MS

A rapid, sensitive and specific method based on high performance liquid chromatography-electrospray ionization-mass spectrometry was developed for the determination of tiopronin in human plasma. In this study, vitamin C and dithiothreitol were used as the reducer and to release and stabilize tiopronin from dimeric mixed forms with endogenous thiols encountered during pretreatment of plasma samples. The separation was successfully achieved on an Agilent SB-Aq column packed with 5 μm C₁₈ silica, using an aqueous formic acid solution (pH 4.5–4.7), 0.5 mM tris(hydroxymethyl)aminomethane and methanol (95:5, v/v) as the mobile phase. Mass spectra were acquired in selective ion monitoring mode, using the [M ? H] ^? ions of tiopronin at m/z 162.0 and the [M ? H]^? of the internal standard sodium cyclamate at m/z 178.0, respectively. This quantitative assay was fully validated with respect to precision, repeatability and accuracy. The correlation coefficients were >0.9995 in the range 0.025–8.15 μg mL^?1 in human plasma. The mean recoveries were above 85%. The limit of quantitation was 0.012 μg mL^?1 with a relative standard deviation of inter-day and intra-day accuracy of less than 15%. This LC-ESI-MS method was also successfully applied to a pharmacokinetic study after oral administration of formulated tiopronin to healthy volunteers. The elimination half-life (T _1/2) was 21.5 ± 11.1 h.     

Simultaneous Determination of Enalapril and Enalaprilat in Human Plasma by LC-MS: Application to a Bioequivalence Study

A rapid, simple and specific liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS) method has been developed and validated for the simultaneous determination of enalapril and its major active metabolite enalaprilat in human plasma. Benazepril hydrochloride was used as the internal standard. Plasma was deproteinized with acetone and centrifuged. The supernatant was transferred and evaporated to dryness and the residue dissolved in mobile phase. Samples were separated on a C18 column with a mobile phase of methanol–20 mM ammonium acetate (53:47, v/v) containing 0.15% trifluoracetic acid (v/v) with a pH of 3.0. Enalapril, enalaprilat and the internal standard were measured by electrospray positive selective ion monitoring mode. The method was validated over a linear range of 1.56–400 ng mL⁻¹ and the limits of quantification were 1.56 ng mL⁻¹ for both enalapril and enalaprilat using 0.1 mL plasma. Extraction efficiency was more than 84% and recoveries were in range of 93.65–101.17%. The intra-day relative standard deviations (RSD) were less than 8.16 and 7.05% and inter-day RSDs were within 8.42 and 5.72% for enalapril and enalaprilat, respectively. The storage stability of QC samples was investigated under various conditions. The method was successfully applied for the evaluation of the pharmacokinetics and bioequivalence of enalapril and enalaprilat in 20 healthy volunteers after an oral dose of 20 mg enalapril maleate.     

LC Determination and Bioequivalence Study of Pantoprazole in Human Plasma

A selective and sensitive liquid chromatography (LC) method with rapid sample processing was developed for determination of pantoprazole in human plasma using omeprazole as internal standard (IS). The plasma sample (100 μL) was deproteined by precipitation with methanol. The supernatant was directly determined by LC using a Diamonsil C₁₈ ODS column and solution of 10 mM Na₂HPO₄ buffer (containing 0.01% H₃PO₄) and acetonitrile (68:32, v/v, pH = 6.8) as mobile phase with UV detector set at 288 nm. The retention time of IS and pantoprazole were 4.9 ± 0.2 and 5.6 ± 0.2 min, respectively. The method was validated with a linear range of 0.03–5.0 μg mL^?1 and the lowest limit of quantification was 0.03 μg mL^?1 for pantoprazole (r = 0.9999). The coefficient of variation for intra-day and inter-day accuracy and precision was less than 9.5%. The mean extraction recovery was 84.1%. Quality control samples were stable when kept at autosampler temperature for 24 h, at ?20 °C for 42 days and after three freeze-thaw cycles. The assay was successfully applied to a randomized, two-period cross-over bioequivalence study in 20 healthy Chinese volunteers following a single oral dose of 40 mg pantoprazole. Various pharmacokinetic parameters including AUC _0～t , AUC _0～∞, C _max, T _max and t _1/2 were determined from plasma concentration of both formulations. The results indicated that the analytical method was a specific, precise, sensitive and rapid procedure for determination of plasma pantoprazole concentration and therefore, a suitable and valuable tool in the investigation of the clinical pharmacokinetics and bioequivalence.     

Determination of Dapoxetine Hydrochloride in Human Plasma by HPLC–MS/MS and Its Application in a Bioequivalence Study

Dapoxetine is used for the treatment of premature ejaculation. The present study developed an HPLC–MS/MS method to determine the levels of dapoxetine in human plasma processed using simple protein precipitation. Dapoxetine-d₇ was selected as the internal standard. The established method was performed using a mass spectrometer equipped with an electrospray ionization source in multiple positive ion reactions to monitor the mode using the precursor-to-product ion transitions of m/z 306.2–157.2 and m/z 313.2–164.2 for dapoxetine-d7 and dapoxetine, respectively. The method was evaluated based on its selectivity, linearity, limit of quantification, precision, accuracy, matrix effects, dilution integrity, stability, and extraction recovery. As a result of the model used in the present study, the validated linear ranges of dapoxetine were determined to be 2.00~1000 ng/mL in plasma, and the selectivity, precision, accuracy, dilution integrity, stability, and extraction recovery met the accepted standard. No matrix interference was observed. The method was successfully validated and applied to pharmacokinetic studies in healthy Chinese volunteers during the fasting and postprandial periods, respectively.     

Determination of Cefaclor in Human Plasma by Reversed-Phase High-Performance Liquid Chromatography with UV Detection and Its Application to the Bioequivalence Studies

Abstract

A selective and sensitive reversed-phase high-performance liquid chromatography method was developed and validated for quantitation of cefaclor in human plasma using cefradine as an internal standard. Calibration curve was linear over range of 0.1–20 mg · L^?1. The intra- and inter-run relative standard deviations of the assay were less than 7%. The mean absolute recoveries determined at the concentrations of 0.3, 3.0, 8.0, and 15.0 mg · L^?1 were 69.9%, 69.9%, 77.1% and 72.0%, respectively. The analytical method established was proved to be specific, precise, sensitive, and suitable for applying in the pharmacokinetic and bioequivalence studies of cefaclor in human.     

Determination of Penciclovir in Human Plasma Using LC with Fluorescence Detection: Application to a Bioequivalence Study

A novel HPLC method with fluorescence detection and one step sample preparation was developed for the determination of penciclovir in human plasma. Plasma samples (200 μL) were deproteinized by precipitation with 100 μL of perchloric acid and centrifuged. Separation was on an Inertsil ODS-3 column with a mixture of methanol–0.1% orthophosphoric acid as mobile phase. The fluorescence detector was set at Ex 270 nm, Em 375 nm. The assay was selective and linear with a limit of quantification of 0.025 mg L^?1. The mean absolute recovery was 98.1%, while the intra- and inter-day coefficients of variation and percent error values of the assay method were all less than 10%. The assay was successfully applied in a randomized cross-over bioequivalence study of three pharmaceutical products containing 250 mg famciclovir (an oral prodrug of penciclovir) in 18 healthy volunteers.     

LC-ESI-MS Method for the Determination of Mizolastine in Human Plasma

A sensitive and rapid liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) method has been developed and validated for the determination of mizolastine in human plasma using dipyridamole as the internal standard (I.S.). Plasma samples were simply pretreated with methanol for deproteinization. Chromatographic separation was performed on an Agilent Zorbax C₁₈ column with a mobile phase of 10 mM ammonium acetate buffer containing 0.1% formic acid–methanol (20:80, v/v) at a flow rate of 1 mL min⁻¹. The electrospray ionization (ESI) interface was employed in a single quadrupole mass spectrometer. The analytes were protonated in the positive ESI interface and detected in single ion monitoring (SIM) mode. Chromatographic separation was achieved in less than 3.5 min. The linearity was established over the range of 0.5–600 ng mL⁻¹. The lower limited of quantification (LLOQ) of the method was 0.5 ng mL⁻¹. The intra- and inter-run standard deviations were both less than 11.2%. The method was applied to study the pharmacokinetics of the mizolastine sustained-release tablets in healthy volunteers.     

High-Performance Liquid Chromatography-Tandem Mass Spectrometry for the Determination of Trospium Chloride in Human Plasma and Its Application in a Bioequivalence Study

A selective, rapid, and sensitive high performance liquid chromatography-tandem mass spectrometry (HPLC-ESI-MS/MS) method was developed and validated for the quantification of trospium chloride in human plasma. With tramadol chloride as the internal standard, sample pretreatment involved a simple liquid-liquid extraction with chloroform-isopropyl alcohol (40/2, v/v) of 0.5 ml plasma. The analysis was carried out on a Hypsil C₁₈ column (150 mm × 2.1 mm, 5.0 μm) with a flow rate of 0.2 ml/min. The mobile phase was methanol-5% acetic acid-20 mM ammonium methylate (55/30/15, v/v/v). The detection was performed by a selected reaction monitoring (SRM) mode via electrospray ionization (ESI). Linear calibration curves were obtained in the concentration range of 0.2–50.0 ng/ml, with a lower limit of quantification of 0.2 ng/ml. The intra- and inter-day precision (RSD) values were below 15%. The method was successfully applied to a clinical bioequivalence study of trospium chloride in Chinese healthy volunteers following oral administration.     

Quantification of Teprenone in Human Plasma by HPLC Coupled to Mass Spectrometry: Application to a Bioequivalence Study

A rapid, sensitive, and specific method has been developed for quantification of teprenone (TEP) in human plasma. The analytes were isolated from plasma by liquid–liquid extraction with t-butyl methyl ether. The extracts were analyzed by high-performance liquid chromatography coupled to mass spectrometry (HPLC–MS); gefarnate was used as internal standard (IS). HPLC separation of the analytes was performed on a C₁₈ column with 1:54:45 (v/v) 1% aqueous acetic acid–methanol–acetonitrile as mobile phase; the flow rate was 0.2 mL min^?1. The compounds were ionized by atmospheric-pressure chemical ionization (APCI). Calibration plots for TEP were linear in the range 20.0–2000.0 ng mL^?1; correlation coefficients were >0.9981. The average extraction efficiency for TEP was >67%, method recovery was >95%, the limit of detection (LOD) was 1.0 ng mL^?1, and the intraday and interday coefficients of variation were <7%. This HPLC–MS procedure was used to assess the bioequivalence of TEP tablet and capsule formulations. A single 150-mg dose of each formulation was administered to 18 healthy male volunteers. The study was conducted using an open, randomized, two-period crossover design with a 1-week wash-out interval. Because the 90% CI for C _max and the ratios of the AUCs were all within the 80–125% range stipulated by the US Food and Drug Administration, it was concluded that the TEP tablet and capsule formulations were bioequivalent in terms of rate and extent of absorption.     

Rapid Determination of Ranitidine in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to a Clinical Pharmacokinetic Study

A rapid and sensitive assay based on high performance liquid chromatography-tandem mass spectrometry(LC-MS/MS) was developed for the determination of ranitidine(RAN) in human plasma with codeine as internal standard(IS).After protein precipitation with acetonitrile,the analyte and IS were separated on a Zorbax SB-Aq C18 column(150 mm×4.6 mm i.d.,5 μm) eluted with a mobile phase consisting of methanol/acetonitrile/10 mmol/L ammonium acetate containing 1% formic acid(pH=2.4)(volume ratio 12.5:12.5:75) at a flow rate of 1.0 mL/min.Detection was performed by electrospray ionization in the positive ion mode followed by the multiple reaction monito-ring(MRM) of the transitions of RAN at m/z 315.1→176.3 and of IS at m/z 300.1→165.1.The method was linear over a concentration range of 1―1000 ng/mL(r=0.9991) with a lower limit of quantitation(LLOQ) of 1 ng/mL and a limit of detection(LOD) of 0.3 ng/mL.Accuracy as relative error was from-0.01% to-1.7% and intra-day and inter-day precisions as relative standard deviation were ≤8.9% and ≤5.5%,respectively.The method was successfully applied to a pharmacokinetic study of ranitidine,getting a single oral dose(160 mg) to healthy volunteers.     

LC-ESI-MS Determination of Bilobalide and Ginkgolides in Canine Plasma

A sensitive and selective method using liquid chromatography with electrospray ionization mass spectrometric detection was developed for the quantification of bilobalide and ginkgolides in canine plasma. The analytes were extracted with diethyl ether-dichloromethane-isopropanol (6:3:1, v/v) after spiking the samples with daidzein (internal standard). The lower limit of quantification (LLOQ) of the method was 2.5 μg L⁻¹ for ginkgolide B and 10.0 μg L⁻¹ for bilabolide, ginkgolide A and ginkgolide C. The accuracy of the method was within 15% of the actual values over a wide range of plasma concentrations. The intra-day and inter-day precision was better than 15% (R.S.D.). Finally, the LC-ESI-MS method was successfully applied to study the pharmacokinetics of ginkgolides and bilabolide after administration of Ginkgo biloba extracts to dogs.     

Fast and Sensitive HPLC-ESI-MS/MS Method for Etoricoxib Quantification in Human Plasma and Application to Bioequivalence Study

Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation. The objective of the current study was to develop a sensitive, fast and high-throughput HPLC-ESI-MS/MS method to measure etoricoxib levels in human plasma using a one-step methanol protein precipitation technique. A tandem mass spectrometer equipped with an electrospray ionization (ESI) source operated in a positive mode and multiple reaction monitoring (MRM) were used for data collection. The quantitative MRM transition ions were m/z 359.15 > 279.10 and m/z 363.10 > 282.10 for etoricoxib and IS. The linear range was from 10.00 to 4000.39 ng/mL and the validation parameters were within the acceptance limits of the European Medicine Agency (EMA) and Food and Drug Analysis (FDA) guidelines. The present method was sensitive (10.00 ng/mL with S/N > 40), simple, selective (K prime > 2), and fast (short run time of 2 min), with negligible matrix effect and consistent recovery, suitable for high throughput analysis. The method was used to quantitate etoricoxib plasma concentrations in a bioequivalence study of two 120 mg etoricoxib formulations. Incurred sample reanalysis results further supported that the method was robust and reproducible.     

Determination of Fluoxetine in Human Plasma by Liquid Chromatography–Mass Spectrometry and Its Application

Abstract

A rapid, simple, and specific liquid chromatography–electrospray ionization–mass spectrometric method has been developed and validated for the determination of fluoxetine in human plasma. The method was validated with a linear range of 0.5–100 ng mL^?1, and the lowest limits of quantification were 0.5 ng mL^?1 for fluoxetine. The extraction efficiencies were about 65% and recoveries of method were in the range of 94.0–97.5%. The intraday relative standard deviation (RSD) was less than 11% and interday RSD was within 12%. The method has been successfully applied to the evaluation of pharmacokinetics and bioequivalence of fluoxetine.     

Development and Validation of LC-ESI-MS/MS Method for the Determination of Alfuzosin in Human Plasma

Journal of Analytical Chemistry - A new liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) method has been developed and validated for alfuzosin quantification in...     

Development and Validation of LC–MS Method for the Determination of Hydroxyzine Hydrochloride in Human Plasma and Subsequent Application in a Bioequivalence Study

A rapid, simple and specific liquid chromatography-electrospray ionization mass spectrometry method has been developed and validated for the determination of hydroxyzine hydrochloride in human plasma. Samples were separated using a Thermo Hypersil-HyPURITYC18 reversed-phase column (150 mm × 2.1 mm i.d., 5 μm). The mobile phase consisted of 50 mM ammonium acetate (pH 4.0)–methanol–acetonitrile (45:36:19, v/v). Hydroxyzine and its internal standard were measured by electrospray ion source in positive selective ion monitoring mode. The method was validated with a linear range of 1.56–200.0 ng mL⁻¹ and the lowest limit of quantification was 1.56 ng mL⁻¹ for hydroxyzine hydrochloride (r ²= 0.9991). The extraction efficiencies were about 70% and recoveries of the method were in the range of 93.5–104.4%. The intra-day relative standard deviation (RSD) was less than 8.0% and inter-day RSD was within 7.4%. QC samples were stable when kept at ambient temperature for 12 h at −20 °C for 30 days and after four freeze–thaw cycles. The method has been successfully applied to the evaluation of pharmacokinetics and bioequivalence of two hydroxyzine hydrochloride formulations in 12 healthy Chinese volunteers after an oral dose of 25 mg.     

LC-MS测定人血浆中班布特罗及其代谢物特布他林的浓度

用高效液相色谱-质谱联用法测定人血浆中班布特罗及其代谢物特布他林的浓度.仪器:Waters公司2690型高效液相色谱系统,Waters公司Platform LCZ质谱检测器,Masslynx工作软件.     

LC-MS-MS快速定量测定人血浆中 ADH及其四种代谢物

ADH是1种双重金属蛋白酶抑制剂,临床用于治疗高血压和充血性心衰.据国外文献报道[1],ADH体内血药浓度很低,主要有4种微量代谢物,分别命名为3087、3308、3433、3653.其中ADH、3653、3087结构中含有游离的巯基,容易发生体外氧化,所以给生物样品的定量、定性分析带来了极大的困难,普通的HPLC方法根本无法实现准确定量.国外同期研究[2]的血药浓度最低检测限(LLQ)也仅能做到0.5 μg/L,且样品制备方法复杂,分析时间长,不能同时测定原药及其代谢物,难以适应临床药理学研究的要求.本实验室以甲基丙烯酸酯(MA)对上述3种含巯基的化合物进行衍生化处理,采用叔丁基甲醚萃取血浆样品,以多反应离子监测(MRM)同时监测10种目标化合物,充分发挥LC-MS-MS高效、灵敏、快速、选择性好、特异性强的特点,建立了ADH及其代谢物的LC-MS-MS方法.与国外同期研究相比,本法提高了灵敏度,简化了样品制备过程,缩短了分析时间,可以同时测定ADH及其代谢物,从而为该药的Ⅰ期临床研究提供了坚实的定量分析基础,同时说明LC-MS-MS在易分解药物及其微量代谢物的研究中具有广泛的应用前景.